morphineWhat was measured
Measured, with no finding
691 endpoints
Show what was measuredHide what was measured
proportion of patients changed to an alternative opioid for intolerable effects
unclear
change to an alternative opioid in up to 40% of patients
PMID 11237376 · one of two readings recorded this
relative potency of transdermal fentanyl to parenteral morphine
increases
about 80 times as potent as
PMID 11237376 · one of two readings recorded this
constipation heterogeneity (Ph)
p = 0.00001, n = 2593
Constipation | 2593/31 | 0.35 (0.27, 0.45) | < 0.00001 | < 0.00001
PMID 20529380 · one of two readings recorded this
constipation (pooled RR)
decreases, p = 0.00001, n = 2593
pooled RR of constipation was 0.35 [95%CI (0.27, 0.45), p < 0.00001]
PMID 20529380 · one of two readings recorded this
nausea/vomiting heterogeneity (Ph)
p = 0.009, n = 2593
Nausea/vomiting | 2593/31 | 0.57 (0.49, 0.67) | < 0.00001 | 0.009
PMID 20529380 · one of two readings recorded this
nausea/vomiting (pooled RR)
decreases, p = 0.00001, n = 2593
pooled RR of nausea/vomiting was 0.57 [95%CI (0.49, 0.67), p < 0.00001]
PMID 20529380 · one of two readings recorded this
quality of life (systematic review, six trials)
unclear
all the data from each trial supported either transdermal fentanyl or sustained-release oral morphine improved QOL of cancer patients
PMID 20529380 · one of two readings recorded this
remission rate heterogeneity (Ph)
no effect, p = 1, n = 2491
Remission rate | 2491/30 | 1.13 (0.92, 1.38) | 0.23 | 1.00
PMID 20529380 · one of two readings recorded this
remission rate of cancer pain (category 2 or above of pain relief on NRS/VAS-based five-category criterion), transdermal fentanyl vs sustained-release oral morphine; constipation, nausea/vomiting, vertigo/somnolence
no effect, remission rate 86.60% fentanyl vs 88.31% morphine, RR 1.13 (95% CI 0.92, 1.38), p = 0.23
Not recorded as a finding: the comparison was against another active treatment
The remission rate in transdermal fentanyl group and sustained-release oral morphine group were 86.60% and 88.31% respectively, there was no significant difference [RR = 1.13, 95% CI (0.92, 1.38), P = 0.23].
PMID 20529380 · one of two readings recorded this
remission rate of pain (category 2 or above of five-category pain relief), transdermal fentanyl versus sustained-release oral morphine, Chinese cancer pain patients
no effect, RR = 1.13, 95% CI (0.92, 1.38), p = 0.23
Not recorded as a finding: the comparison was against another active treatment
The remission rate in transdermal fentanyl group and sustained-release oral morphine group were 86.60% and 88.31% respectively, there was no significant difference [RR = 1.13, 95% CI (0.92, 1.38), P = 0.23].
PMID 20529380 · one of two readings recorded this
remission rate of pain (pooled RR)
no effect, p = 0.23, n = 2491
there was no significant difference [RR = 1.13, 95% CI (0.92, 1.38), P = 0.23]
PMID 20529380 · one of two readings recorded this
remission rate of pain
no effect
The remission rate in transdermal fentanyl group and sustained-release oral morphine group were 86.60% and 88.31% respectively
PMID 20529380 · one of two readings recorded this
vertigo/somnolence heterogeneity (Ph)
p = 0.08, n = 2300
Vertigo/somnolence | 2300/28 | 0.59 (0.51, 0.68) | < 0.00001 | 0.08
PMID 20529380 · one of two readings recorded this
vertigo/somnolence (pooled RR)
decreases, p = 0.00001, n = 2300
Pooled RR of vertigo/somnolence was 0.59 [95%CI (0.51, 0.68), p < 0.00001]
PMID 20529380 · one of two readings recorded this
retention in treatment
no effect
The retention in treatment appeared superior to 80% in all the three studies (without significant difference with controls)
PMID 23740540 · one of two readings recorded this
anxiety symptoms
decreases, p = 0.008
anxiety symptoms (P value = 0.008)
PMID 23740540 · one of two readings recorded this
depressive symptoms
decreases, p = 0.001
depressive symptoms (measured using the Beck Depression Inventory; P value < 0.001)
PMID 23740540 · one of two readings recorded this
friends and acquaintances
unclear, p = 0.003
friend and acquaintances (5.6 vs. 4.4, P value = 0.003)
PMID 23740540 · one of two readings recorded this
housing
unclear, p = 0.023
housing (6.1 vs. 4.7, P value < 0.023)
PMID 23740540 · one of two readings recorded this
leisure time
unclear, p = 0.001
leisure time (5.4 vs. 3.7, P value < 0.001)
PMID 23740540 · one of two readings recorded this
mental health
unclear, p = 0.002
mental health (5.0 vs. 3.4, P value = 0.002)
PMID 23740540 · one of two readings recorded this
opiate withdrawal symptoms
decreases, p = 0.06
a trend for less severe opiate withdrawal symptoms in comparison with methadone (withdrawal score 2.2 vs. 4.8, P value = 0.06)
PMID 23740540 · one of two readings recorded this
partnerships
unclear, p = 0.034
partnerships (5.7 vs. 4.2, P value = 0.034)
PMID 23740540 · one of two readings recorded this
physical complaints
decreases, p = 0.001
physical complaints (measured using the Beschwerde-Liste (BL); P value < 0.001)
PMID 23740540 · one of two readings recorded this
retention in treatment, opioid use, depressive symptoms (Beck Depression Inventory) and withdrawal severity with slow-release oral morphine versus methadone or buprenorphine maintenance
no effect, retention in treatment not significantly different among compared interventions
Not recorded as a finding: the comparison was against another active treatment
Retention in treatment was not significantly different among compared interventions while the adverse effects were more frequent with the people given SROM.
PMID 23740540 · one of two readings recorded this
self esteem
unclear, p = 0.002
self esteem (8.2 vs. 5.7, P value = 0.002)
PMID 23740540 · one of two readings recorded this
proportion of participants with adverse events (constipation, somnolence, nausea, dry mouth, vomiting, anorexia, dizziness) in cancer pain trials of morphine, fentanyl, oxycodone and codeine
pooled adverse event incidence across all four opioids: constipation 25%, somnolence 23%, nausea 21%, dry mouth 17%
Not recorded as a finding: the intervention held more than the compound
For opioids used to treat cancer pain adverse event incidence rates were 25% for constipation, 23% for somnolence, 21% for nausea, 17% for dry mouth, and 13% for vomiting, anorexia, and dizziness.
PMID 24874470 · one of two readings recorded this
incidence of pain relief, nalbuphine versus morphine, pooled relative risk
no effect, p = 0.9
Not recorded as a finding: the comparison was against another active treatment
In pooled analyses, there was no significant difference of incidence of pain relief between nalbuphine and morphine (the pooled RRs,1.01; 95% confidence interval [CI], 0.91 to 1.11; P = 0.90).
PMID 26039709 · one of two readings recorded this
incidence of pain relief (patients needing no additional analgesic), nalbuphine vs morphine, pooled RR; also pruritus, nausea, vomiting, respiratory depression
no effect, p = 0.9
Not recorded as a finding: the comparison was against another active treatment
In pooled analyses, there was no significant difference of incidence of pain relief between nalbuphine and morphine (the pooled RRs,1.01; 95% confidence interval [CI], 0.91 to 1.11; P = 0.90).
PMID 26039709 · one of two readings recorded this
nausea
decreases, p = 0.048
0.78(95%CI, 0.602–0.997; P = 0.048) for nausea
PMID 26039709 · one of two readings recorded this
nausea
no effect
0.46(95%CI: 0.20–1.04) for nausea
PMID 26039709 · one of two readings recorded this
nausea
no effect
0.83(95%CI: 0.64–1.09) for Nausea
PMID 26039709 · one of two readings recorded this
pain relief (incidence), Bayesian random effects
no effect
Relative Risk of pain relief comparing nalbuphine and morphine using random effects model was 1.102(95% credible interval: 0.6697–1.627)
PMID 26039709 · one of two readings recorded this
pain relief (incidence)
no effect, p = 0.9, n = 618
In pooled analyses, there was no significant difference of incidence of pain relief between nalbuphine and morphine (the pooled RRs,1.01; 95% confidence interval [CI], 0.91 to 1.11; P = 0.90)
PMID 26039709 · one of two readings recorded this
pain relief (incidence)
no effect
1.09(95%CI:0.85–1.41
PMID 26039709 · one of two readings recorded this
pain relief (incidence)
no effect
0.96(95%CI: 0.76–1.21
PMID 26039709 · one of two readings recorded this
pain relief (incidence)
no effect
1.03(95%CI: 0.70–1.51
PMID 26039709 · one of two readings recorded this
pain relief (incidence)
no effect
0.99(95%CI: 0.94–1.04
PMID 26039709 · one of two readings recorded this
pain relief (incidence)
no effect
1.01(95%CI:0.89–1.16
PMID 26039709 · one of two readings recorded this
pruritus
decreases
0.17(95%CI, 0.09–0.34; P < 0.000) for pruritus
PMID 26039709 · one of two readings recorded this
pruritus
decreases
0.22(95%CI: 0.07–0.66) for pruritus
PMID 26039709 · one of two readings recorded this
pruritus
decreases
0.12(95%CI: 0.02–0.97) for Pruritus
PMID 26039709 · one of two readings recorded this
respiratory depression
decreases, p = 0.001
0.27(95%CI, 0.12–0.57; P = 0.001) for respiratory depression
PMID 26039709 · one of two readings recorded this
vomiting
decreases, p = 0.001
0.65(95%CI, 0.50–0.85; P = 0.001) for vomiting
PMID 26039709 · one of two readings recorded this
vomiting
no effect
0.40(95%CI: 0.08–1.94) for vomiting
PMID 26039709 · one of two readings recorded this
vomiting
decreases
0.72(95%CI: 0.55–0.94) for Vomiting
PMID 26039709 · one of two readings recorded this
last VAS score
decreases, p = 0.001, n = 320
WMD −1.53; 95% CI −1.98 to −1.09; p<0.001
PMID 26078306 · one of two readings recorded this
last VAS score
decreases, p = 0.001
last VAS scores: WMD −1.46; 95% CI −1.63 to −1.29; p<0.001
PMID 26078306 · one of two readings recorded this
last VAS score
decreases, p = 0.001
Mild pain score in control group (mean VAS value ≤3) | −1.76 (−1.96 to −1.56) | <0.001 | 47 | 0.09
PMID 26078306 · one of two readings recorded this
last VAS score
decreases, p = 0.001
Mixed with epinephrine | −1.54 (−2.06 to −1.01) | <0.001 | 74 | 0.0003
PMID 26078306 · one of two readings recorded this
last VAS score
decreases, p = 0.001
Small sample size (less than 10 in control group) | −1.52 (−2.01 to −1.04) | <0.001 | 67 | 0.001
PMID 26078306 · one of two readings recorded this
last VAS score
decreases, p = 0.001
Spinal anaesthesia | −1.68 (−2.16 to −1.19) | <0.001 | 66 | 0.003
PMID 26078306 · one of two readings recorded this
last VAS score
decreases, p = 0.001
Treated with a cooling system | −1.70 (−1.89 to −1.50) | <0.001 | 41 | 0.09
PMID 26078306 · one of two readings recorded this
mean VAS score
decreases, p = 0.001, n = 320
WMD −1.58; 95% CI −2.16 to −1.01; p<0.001
PMID 26078306 · one of two readings recorded this
mean VAS score
decreases, p = 0.001
mean VAS scores: WMD −1.75; 95% CI −2.16 to −1.33; p<0.001
PMID 26078306 · one of two readings recorded this
mean VAS score
decreases, p = 0.001
Mild pain score in control group (mean VAS value ≤3) | −1.72 (−2.39 to −1.05) | <0.001 | 64 | 0.005
PMID 26078306 · one of two readings recorded this
mean VAS score
decreases, p = 0.001
Mixed with epinephrine | −1.10 (−1.42 to −0.77) | <0.001 | 31 | 0.18
PMID 26078306 · one of two readings recorded this
mean VAS score
decreases, p = 0.001
Small sample size (less than 10 in control group) | −1.56 (−2.16 to −0.96) | <0.001 | 59 | 0.009
PMID 26078306 · one of two readings recorded this
mean VAS score
decreases, p = 0.001
Spinal anaesthesia | −1.72 (−2.39 to −1.05) | <0.001 | 64 | 0.005
PMID 26078306 · one of two readings recorded this
patients requiring supplementary analgesia
decreases, p = 0.02
RR 0.60; 95% CI 0.39 to 0.93; p=0.02
PMID 26078306 · one of two readings recorded this
patients requiring supplementary analgesia
no effect, p = 0.08
RR 0.64; 95% CI 0.39 to 1.05; p=0.08
PMID 26078306 · one of two readings recorded this
patients requiring supplementary analgesia
no effect, p = 0.06
RR 0.66; 95% CI 0.43 to 1.02; p=0.06
PMID 26078306 · one of two readings recorded this
patients requiring supplementary analgesia
decreases, p = 0.03
Spinal anaesthesia | 0.62 (0.41 to 0.95) | 0.03 | 66 | 0.007
PMID 26078306 · one of two readings recorded this
postoperative pain intensity on a visual analogue scale converted to 0-10, mean VAS and last VAS after single-dose intra-articular injection following knee arthroscopy
decreases, bupivacaine plus morphine vs placebo, mean VAS WMD -1.58 (95% CI -2.16 to -1.01)
Not recorded as a finding: the intervention held more than the compound
The bupivacaine plus morphine group demonstrated significantly lower mean VAS scores (WMD −1.58; 95% CI −2.16 to −1.01; p<0.001) and last VAS scores (WMD −1.53; 95% CI −1.98 to −1.09; p<0.001) compared to the placebo group.
PMID 26078306 · one of two readings recorded this
short-term side effects
no effect, p = 0.29
RR 1.67; 95% CI 0.65 to 4.26; p=0.29
PMID 26078306 · one of two readings recorded this
time to first analgesic request after knee arthroscopy, single-dose intra-articular bupivacaine plus morphine versus saline placebo, pooled WMD
no effect, WMD 3.46; 95% CI -1.81 to 8.72, p = 0.2
Not recorded as a finding: the intervention held more than the compound
The combined data suggested no significant difference (WMD 3.46; 95% CI −1.81 to 8.72; p=0.20) between the bupivacaine plus morphine group and the placebo group.
PMID 26078306 · one of two readings recorded this
time to first analgesic request
no effect, p = 0.2
WMD 3.46; 95% CI −1.81 to 8.72; p=0.20
PMID 26078306 · one of two readings recorded this
patients requiring supplementary analgesia
no effect, p = 0.1
RR = 0.78; 95% CI 0.57 to 1.05; p = 0.10
PMID 26474401 · one of two readings recorded this
patients requiring supplementary analgesia
no effect, p = 0.09
it was 0.77 (95% CI 0.57 to 1.04; p = 0.09)
PMID 26474401 · one of two readings recorded this
patients requiring supplementary analgesia
no effect, p = 0.45
or 0.87 (95% CI 0.62 to 1.24; p = 0.45)
PMID 26474401 · one of two readings recorded this
postoperative pain intensity on a visual analogue scale (0-10) in the immediate period 0-2 h after intra-articular injection following knee arthroscopy
decreases, p = 0.007
Not recorded as a finding: the comparison was against another active treatment
Overall, the combined group showed a statistically significant lower postoperative pain intensity compared with morphine group (WMD -1.16; 95% CI -2.01 to -0.31; p = 0.007), while significant heterogeneity was observed (I 2 = 82%; p<0.00001).
PMID 26474401 · one of two readings recorded this
time to first analgesic request
increases, p = 0.03
WMD = 2.05; 95% CI 0.19 to 3.92; p = 0.03
PMID 26474401 · one of two readings recorded this
time to first analgesic request
increases, p = 0.05
the overall WMD was 2.20 (95% CI 0.01 to 4.40; p = 0.05)
PMID 26474401 · one of two readings recorded this
VAS pain intensity
decreases, p = 0.007
WMD -1.16; 95% CI -2.01 to -0.31; p = 0.007
PMID 26474401 · one of two readings recorded this
VAS pain intensity
decreases, p = 0.03
-1.05 (95% CI -2.00 to -0.10; p = 0.03)
PMID 26474401 · one of two readings recorded this
VAS pain intensity
decreases, p = 0.003
-1.38 (95% CI -2.29 to -0.48; p = 0.003)
PMID 26474401 · one of two readings recorded this
VAS pain intensity
no effect, p = 0.15
Spinal anesthesia | -0.54 | 0.15 | 64% | 0.01
PMID 26474401 · one of two readings recorded this
VAS pain intensity
decreases, p = 0.03
Mixed with epinephrine | -1.08 | 0.03 | 84% | <0.000001
PMID 26474401 · one of two readings recorded this
Incidence of adverse events
no effect, n = 314
no statistical difference was obtained regarding the incidence of adverse events (risk ratio (RR) 1.09, 95% CI 0.51 to 2.36; participants = 314; studies = 8; low quality evidence)
PMID 27140500 · one of two readings recorded this
Pain intensity (VAS)
no effect, n = 297
late phase (six to 30 hours) (MD -0.88, 95% CI -1.81 to 0.04; participants = 297; studies = 7; low quality evidence)
PMID 27140500 · one of two readings recorded this
Pain intensity (VAS)
no effect, n = 297
medium phase (two to six hours) (MD -0.47, 95% CI -1.09 to 0.14; participants = 297; studies = 7; low quality evidence)
PMID 27140500 · one of two readings recorded this
Pain intensity (VAS)
no effect, n = 72
IA morphine was similar to intramuscular (IM) morphine for pain intensity at early phase (MD 0.21, 95% CI -0.48 to 0.90; participants = 72; studies = 2; very low quality evidence)
PMID 27140500 · one of two readings recorded this
Pain intensity (VAS)
unclear, n = 248
IA morphine was not better than local anaesthetic agents at early phase (MD 1.43, 95% CI 0.49 to 2.37; participants = 248; studies = 5; low quality evidence)
PMID 27140500 · one of two readings recorded this
Pain intensity (VAS)
no effect, n = 80
NSAIDs at early phase (MD 0.95, 95% CI -0.95 to 2.85; participants = 80; studies = 2; very low quality evidence)
PMID 27140500 · one of two readings recorded this
Pain intensity (VAS)
no effect, n = 105
No significant difference was found between 1 mg and 2 mg morphine for pain intensity at early phase (MD -0.56, 95% CI -1.93 to 0.81; participants = 105; studies = 2; low quality evidence)
PMID 27140500 · one of two readings recorded this
Pain intensity (VAS)
decreases, n = 97
4 mg/5 mg morphine provided better analgesia than 1 mg morphine at late phase (MD 0.67, 95% CI 0.08 to 1.25; participants = 97; studies = 3; low quality evidence)
PMID 27140500 · one of two readings recorded this
time to first analgesic request after knee arthroscopy, intra-articular morphine versus placebo or bupivacaine
no effect
Not recorded as a finding: sentence pools a placebo comparator with an active comparator (bupivacaine), so it does not isolate the compound against no compound
Meta-analysis indicated that there was no difference between IA morphine and placebo or bupivacaine in time to first analgesic request.
PMID 27140500 · one of two readings recorded this
cumulative morphine consumption at 24 h and 48 h after spine surgery, pregabalin versus placebo
decreases, WMD -7.07, 95% CI -9.84, -4.30 at 24 h
Not recorded as a finding: the compound is what was measured, not what was given
The pooled results indicated that pregabalin can reduce the cumulative consumption of morphines at 24 hours (WMD = –7.07, 95% CI –9.84, –4.30, P = 0.000, Fig. 7) and at 48 hours (WMD = –6.52, 95% CI –7.78, –5.25, P = 0.000, Fig. 7).
PMID 28296725 · one of two readings recorded this
cumulative morphine consumption at 24 h and 48 h after spine surgery, with pregabalin as the exposure
decreases, pregabalin vs placebo, WMD -7.07 at 24 h and -6.52 at 48 h
Not recorded as a finding: the compound is what was measured, not what was given
The pooled results indicated that pregabalin can reduce the cumulative consumption of morphines at 24 hours (WMD = –7.07, 95% CI –9.84, –4.30, P = 0.000, Fig. 7) and at 48 hours (WMD = –6.52, 95% CI –7.78, –5.25, P = 0.000, Fig. 7).
PMID 28296725 · one of two readings recorded this
cumulative morphine consumption
decreases
WMD = –7.07, 95% CI –9.84, –4.30, P = 0.000
PMID 28296725 · one of two readings recorded this
cumulative morphine consumption
decreases
WMD = –6.52, 95% CI –7.78, –5.25, P = 0.000
PMID 28296725 · one of two readings recorded this
cumulative morphine consumption
decreases, p = 0.05
Both low doses of pregabalin and high doses of pregabalin can reduce the cumulative morphine consumption at 24 hours and 48 hours (P < 0.05)
PMID 28296725 · one of two readings recorded this
dizziness
no effect, p = 0.139
RR = 1.37, 95% CI 0.90, 2.07, P = 0.139
PMID 28296725 · one of two readings recorded this
headache
no effect, p = 0.54
RR = 1.19, 95% CI 0.68, 2.08, P = 0.540
PMID 28296725 · one of two readings recorded this
nausea
decreases, p = 0.001
RR = 0.57, 95% CI 0.41, 0.79, P = 0.001
PMID 28296725 · one of two readings recorded this
sedation
no effect, p = 0.679
RR = 1.17, 95% CI 0.56, 2.42, P = 0.679
PMID 28296725 · one of two readings recorded this
VAS with mobilization
no effect, p = 0.203
WMD = –17.85, 95% CI –45.32, 9.62, P = 0.203
PMID 28296725 · one of two readings recorded this
VAS with mobilization
no effect, p = 0.088
WMD = –6.70, 95% CI –14.41, 1.01, P = 0.088
PMID 28296725 · one of two readings recorded this
VAS with mobilization
no effect, p = 0.242
WMD = –4.36, 95% CI –11.67, 2.94, P = 0.242
PMID 28296725 · one of two readings recorded this
VAS with rest
no effect, p = 0.082
WMD = –1.91, 95% CI –4.07, 0.24, P = 0.082
PMID 28296725 · one of two readings recorded this
VAS with rest
decreases, p = 0.005
WMD = –2.66, 95% CI –4.51, –0.81, P = 0.005
PMID 28296725 · one of two readings recorded this
VAS with rest
decreases
WMD = –4.33, 95% CI –6.38, –2.99, P = 0.000
PMID 28296725 · one of two readings recorded this
VAS with rest
decreases, p = 0.05
The pooled results indicated that a high dose of pregabalin can reduce the VAS score with rest at 12 hours, 24 hours, and 48 hours with a significant difference (P < 0.05)
PMID 28296725 · one of two readings recorded this
visual disturbances
no effect, p = 0.142
RR = 2.00, 95% CI 0.79, 5.02, P = 0.142
PMID 28296725 · one of two readings recorded this
Adverse drug reaction events
Li et al. (2013) | RCT | 57.4 ± 6.6 | 26 | 1 | 30 | 57.1 ± 8.5 | 25 | 4 | 27 | Dizziness, nausea, vomiting
PMID 28533424 · one of two readings recorded this
Adverse drug reaction events
Li et al. (2014) | RCT | 67 ± 6 | 60 | 24 | 62 | 69 ± 6 | 61 | 50 | 62 | Dizziness, nausea, vomiting, sleepiness
PMID 28533424 · one of two readings recorded this
Adverse drug reaction events
Qi et al. (2011) | RCT | 57.7 ± 6.7 | 27 | 2 | 28 | 57 ± 8.6 | 25 | 5 | 25 | Dizziness, nausea, vomiting
PMID 28533424 · one of two readings recorded this
Adverse drug reaction events
Shen et al. (2013) | RCT | 53 ± 9 | 34 | 5 | 36 | 53 ± 10 | 33 | 13 | 36 | Dizziness, nausea, vomiting, poor appetite
PMID 28533424 · one of two readings recorded this
Adverse drug reaction events
Shi et al. (2013) | RCT | 58.5 ± 8.3 | 41 | 5 | 43 | 58.5 ± 8.3 | 39 | 14 | 43 | Dizziness, nausea, vomiting
PMID 28533424 · one of two readings recorded this
Adverse drug reaction events
Sun et al. (2014) | RCT | 58.2 ± 9.0 | NA | 2 | 31 | 58.5 ± 15.1 | NA | 4 | 25 | Dizziness, nausea, vomiting
PMID 28533424 · one of two readings recorded this
Adverse drug reaction events
Yao et al. (2015) | RCT | NA | 30 | 6 | 40 | NA | 31 | 8 | 40 | NA
PMID 28533424 · one of two readings recorded this
Adverse drug reaction events
Zhang et al. (2012) | RCT | 56.2 ± 3.2 | 38 | 5 | 40 | 56.4 ± 2.3 | 39 | 13 | 40 | Dizziness, nausea, vomiting
PMID 28533424 · one of two readings recorded this
Adverse drug reactions (pooled)
decreases
RR = 0.44, 95% CI (0.30–0.65)
PMID 28533424 · one of two readings recorded this
effective pain relief case number and adverse drug reaction rate in Chinese cancer patients, dezocine injection versus morphine injection
no effect, RR = 0.97, 95% CI (0.77–1.22)
Not recorded as a finding: the comparison was against another active treatment
In the summary result, we did not find any significant association between dezocine injection and morphine injection for the efficacy of persistence of pain in patients with cancer among Chinese populations [RR = 0.97, 95% CI (0.77–1.22)].
PMID 28533424 · both readings recorded this
Effective pain relief (cases effective)
Gan et al. (2012) | RCT | NA | 20 | NA | 23 | NA | 21 | NA | 23 | NA
PMID 28533424 · one of two readings recorded this
Effective pain relief (cases effective)
Li et al. (2013) | RCT | 57.4 ± 6.6 | 26 | 1 | 30 | 57.1 ± 8.5 | 25 | 4 | 27 | Dizziness, nausea, vomiting
PMID 28533424 · one of two readings recorded this
Effective pain relief (cases effective)
Li et al. (2014) | RCT | 67 ± 6 | 60 | 24 | 62 | 69 ± 6 | 61 | 50 | 62 | Dizziness, nausea, vomiting, sleepiness
PMID 28533424 · one of two readings recorded this
Effective pain relief (cases effective)
Qi et al. (2011) | RCT | 57.7 ± 6.7 | 27 | 2 | 28 | 57 ± 8.6 | 25 | 5 | 25 | Dizziness, nausea, vomiting
PMID 28533424 · one of two readings recorded this
Effective pain relief (cases effective)
Shen et al. (2013) | RCT | 53 ± 9 | 34 | 5 | 36 | 53 ± 10 | 33 | 13 | 36 | Dizziness, nausea, vomiting, poor appetite
PMID 28533424 · one of two readings recorded this
Effective pain relief (cases effective)
Shi et al. (2013) | RCT | 58.5 ± 8.3 | 41 | 5 | 43 | 58.5 ± 8.3 | 39 | 14 | 43 | Dizziness, nausea, vomiting
PMID 28533424 · one of two readings recorded this
Effective pain relief (cases effective)
Yao et al. (2015) | RCT | NA | 30 | 6 | 40 | NA | 31 | 8 | 40 | NA
PMID 28533424 · one of two readings recorded this
Effective pain relief (cases effective)
Zhang et al. (2012) | RCT | 56.2 ± 3.2 | 38 | 5 | 40 | 56.4 ± 2.3 | 39 | 13 | 40 | Dizziness, nausea, vomiting
PMID 28533424 · one of two readings recorded this
Effective pain relief (pooled)
no effect
RR = 0.97, 95% CI (0.77–1.22)
PMID 28533424 · one of two readings recorded this
Blurred vision
no effect, p = 0.853
blurred vision (RR = 0.85, 95% CI 0.16, 4.57, P =.853, Fig. 13F, NNT = 13.5)
PMID 28538404 · one of two readings recorded this
Correlation of pregabalin dose with VAS score at rest
no effect, p = 0.139
no correlation between the dosage of pregabalin and the VAS score with rest at 12 hours (r = −0.437, P =.139; Fig. 11B)
PMID 28538404 · one of two readings recorded this
Correlation of pregabalin dose with VAS score at rest
no effect, p = 0.211
24 hours (r = −0.496, P =.211; Fig. 11C)
PMID 28538404 · one of two readings recorded this
Correlation of pregabalin dose with VAS score at rest
decreases, p = 0.031
There was a negative correlation between the dosage of pregabalin and the VAS score at 6 hours (r = −0.623, P =.031; Fig. 11A)
PMID 28538404 · one of two readings recorded this
Dizziness
no effect, p = 0.212
dizziness (RR = 1.61, 95% CI 0.76, 3.38, P =.212, Fig. 13E, NNH = 4.61)
PMID 28538404 · one of two readings recorded this
Headache
no effect, p = 0.959
headache (RR = 1.01, 95% CI 0.74, 1.38, P =.959, Fig. 14, NNT = 190.88)
PMID 28538404 · one of two readings recorded this
Nausea
unclear, p = 0.157
nausea (RR = 0.60, 95% CI 0.42, 0.88, P =.157, NNT = 8.32, Fig. 13A)
PMID 28538404 · one of two readings recorded this
Pruritus
no effect, p = 0.835
pruritus (RR = 1.16, 95% CI 0.30, 4.52, P =.835, NNH = 45.3, Fig. 13D)
PMID 28538404 · one of two readings recorded this
Respiratory depression
no effect, p = 0.647
respiratory depression (RR = 0.71, 95% CI 0.17, 3.02, P =.647, NNT = 41.66, Fig. 13C)
PMID 28538404 · one of two readings recorded this
Total morphine consumption
decreases
gabapentin can reduce total morphine consumption (WMD = −168.60, 95% CI −231.78, −105.42, P =.000, Fig. 12)
PMID 28538404 · one of two readings recorded this
total postoperative morphine consumption (WMD) after laparoscopic cholecystectomy, with pregabalin versus placebo as the exposure
decreases, WMD = −168.60, 95% CI −231.78, −105.42
Not recorded as a finding: the compound is what was measured, not what was given
The pooled results indicated that gabapentin can reduce total morphine consumption (WMD = −168.60, 95% CI −231.78, −105.42, P =.000, Fig. 12).
PMID 28538404 · one of two readings recorded this
VAS pain score at rest
decreases, p = 0.032
gabapentin can decrease VAS scores at 12 hours (WMD = −9.46, 95% CI −18.13, −0.79, P =.032, Fig. 6)
PMID 28538404 · one of two readings recorded this
VAS pain score at rest
decreases, p = 0.005
gabapentin can decrease VAS scores at 24 hours (WMD = −3.99, 95% CI −6.80, −1.19, P =.005, Fig. 7)
PMID 28538404 · one of two readings recorded this
VAS pain score at rest
decreases
the preoperative administration of pregabalin can decrease the VAS score with rest at 6 hours (WMD = −11.27, 95% CI −16.92, −5.62, P =.000, Fig. 3)
PMID 28538404 · one of two readings recorded this
VAS pain score with mobilization
decreases, p = 0.011
pregabalin can decrease the VAS score with mobilization at 12 hours (WMD = −5.80, 95% CI −10.26, −1.35, P =.011, Fig. 9)
PMID 28538404 · one of two readings recorded this
VAS pain score with mobilization
decreases, p = 0.021
pregabalin can decrease the VAS score with mobilization at 24 hours (WMD = −6.37, 95% CI −11.80, −0.94, P =.021, Fig. 10)
PMID 28538404 · one of two readings recorded this
VAS pain score with mobilization
decreases
the preoperative administration of pregabalin can decrease the VAS score with mobilization at 6 hours (WMD = −8.74, 95% CI −13.07, −4.42, P =.000, Fig. 8)
PMID 28538404 · one of two readings recorded this
VAS score at rest, nausea and vomiting: high dose vs low dose
decreases, p = 0.05
The pooled results indicated that a high dose of gabapentin can reduce the VAS score with rest at 6, 12, and 24 hours and nausea and vomiting compared to a low dose (P <.05)
PMID 28538404 · one of two readings recorded this
Vomiting
decreases, p = 0.017
vomiting (RR = 0.56, 95% CI 0.35, 0.90, P =.017, NNT = 8.02, Fig. 13B)
PMID 28538404 · one of two readings recorded this
Itching
increases, p = 0.038
ITM was associated with an increase of the occurrence of itching (RR = 2.50, 95% CI 1.05, 5.93, P = 0.038, Fig. 7)
PMID 28814320 · one of two readings recorded this
Postoperative nausea and vomiting (PONV)
no effect, p = 0.769
There were no significant differences between the groups in the occurrence of PONV (RR = 1.10, 95% CI 0.57, 2.12, P = 0.769, Fig. 6)
PMID 28814320 · one of two readings recorded this
postoperative VAS pain (100-point) at 6, 12, 24, 48 and 72 h, total morphine consumption, PONV and itching, intrathecal morphine versus femoral nerve block after total knee arthroplasty
decreases, WMD = −10.27, 95% CI −12.16, −8.39, p = 0.001
Not recorded as a finding: the comparison was against another active treatment
The results of the meta-analysis indicated that ITM can decrease VAS scores at 24 h (WMD = −10.27, 95% CI −12.16, −8.39, P = 0.001, Fig. 4) when compared with the FNB group.
PMID 28814320 · one of two readings recorded this
Postoperative VAS pain score
decreases
ITM can decrease VAS scores at 12 h (WMD = −9.90, 95% CI −15.05, −4.74, P = 0.000, Fig. 4)
PMID 28814320 · one of two readings recorded this
Postoperative VAS pain score
decreases, p = 0.001
ITM can decrease VAS scores at 24 h (WMD = −10.27, 95% CI −12.16, −8.39, P = 0.001, Fig. 4)
PMID 28814320 · one of two readings recorded this
Postoperative VAS pain score
decreases
ITM can decrease VAS scores at 48 h (WMD = −10.27, 95% CI −12.16, −8.39, P = 0.000, Fig. 4)
PMID 28814320 · one of two readings recorded this
Postoperative VAS pain score
decreases, p = 0.006
ITM can decrease VAS scores at 6 h (WMD = −3.04, 95% CI −5.19, −0.89, P = 0.006, Fig. 4)
PMID 28814320 · one of two readings recorded this
Postoperative VAS pain score
decreases
ITM can decrease VAS scores at 72 h (WMD = −9.00, 95% CI −10.39, −7.61, P = 0.000, Fig. 4)
PMID 28814320 · one of two readings recorded this
Postoperative VAS pain score
no effect
indicate that there was no significant difference between the CFNB and SFNB in terms of VAS at 6, 12 and 24 h
PMID 28814320 · one of two readings recorded this
Total morphine consumption
decreases
ITM can reduce total morphine consumption at 12 h (WMD = −1.17, 95% CI −1.61, −0.73, P = 0.000, Fig. 5)
PMID 28814320 · one of two readings recorded this
Total morphine consumption
decreases
24 h (WMD = −3.96, 95% CI −4.43, −3.48, P = 0.000, Fig. 5)
PMID 28814320 · one of two readings recorded this
Total morphine consumption
decreases
48 h (WMD = −2.76, 95% CI −3.72, −1.80, P = 0.000, Fig. 5)
PMID 28814320 · one of two readings recorded this
VAS pain at 6, 12, 24, 48 and 72 h after total knee arthroplasty, 0-100 VAS, intrathecal morphine versus femoral nerve block
decreases, WMD = −10.27, 95% CI −12.16, −8.39 at 24 h, p = 0.001
Not recorded as a finding: the comparison was against another active treatment
The results of the meta-analysis indicated that ITM can decrease VAS scores at 24 h (WMD = −10.27, 95% CI −12.16, −8.39, P = 0.001, Fig. 4) when compared with the FNB group.
PMID 28814320 · one of two readings recorded this
Average pain inventory (API)
no effect, p = 0.96
average pain inventory (API) (MD =0.01, 95% CI -0.22 – 0.23; p = 0.96)
PMID 30249205 · one of two readings recorded this
composite pain relief rate, Average Pain Inventory and Worst Pain Inventory, and adverse events, oxycodone versus morphine in cancer pain
no effect, MD =0.99, 95% CI -0.88 – 1.11, p = 0.87
Not recorded as a finding: the comparison was against another active treatment
The pooling analysis revealed that there was no difference in composite PRR between oxycodone and morphine (MD =0.99, 95% CI -0.88 – 1.11; p = 0.87).
PMID 30249205 · one of two readings recorded this
Constipation
no effect, p = 0.79
constipation (OR = 1.04, 95% CI 0.77–1.41; p = 0.79)
PMID 30249205 · one of two readings recorded this
Diarrhea
no effect, p = 0.98
diarrhea (OR = 1.01, 95% CI 0.60–1,67; p = 0.98)
PMID 30249205 · one of two readings recorded this
Nausea
no effect, p = 0.22
nausea (OR = 1.20, 95% CI 0.90–1.59; p = 0.22)
PMID 30249205 · one of two readings recorded this
pain relief rate, average pain inventory and worst pain inventory in cancer pain, oxycodone versus morphine
no effect, MD =0.99, 95% CI -0.88 – 1.11, p = 0.87
Not recorded as a finding: the comparison was against another active treatment
The pooling analysis revealed that there was no difference in composite PRR between oxycodone and morphine (MD =0.99, 95% CI -0.88 – 1.11; p = 0.87).
PMID 30249205 · one of two readings recorded this
Pain relief rate (PRR), composite
no effect, p = 0.87
(MD =0.99, 95% CI -0.88 – 1.11; p = 0.87)
PMID 30249205 · one of two readings recorded this
Somnolence
no effect, p = 0.1
the somnolence (OR = 1.35, 95% CI 0.95–1.93; p = 0.10)
PMID 30249205 · one of two readings recorded this
Vomiting
no effect, p = 0.33
vomiting (OR = 1.33, 95% CI 0.75–2.38; p = 0.33)
PMID 30249205 · one of two readings recorded this
Worst pain inventory (WPI)
no effect, p = 0.72
worst pain inventory (WPI) (MD = − 0.05, 95% CI -0.21 – 0.30; p = 0.72)
PMID 30249205 · one of two readings recorded this
Cardiogenic shock
no effect
cardiogenic shock (RR 1.48; 95% CI 1.00 to 2.18; I2=0%)
PMID 30878985 · one of two readings recorded this
Heart failure
no effect
heart failure (RR 1.17; 95% CI 0.91 to 1.51; I2=33%)
PMID 30878985 · one of two readings recorded this
Hypotension
no effect
hypotension (RR 0.93; 95% CI 0.49 to 1.74; I2=5%)
PMID 30878985 · one of two readings recorded this
In-hospital mortality
increases
Adjusted pooled results showed an increased risk of in-hospital mortality in the morphine group (RR 1.45; 95% CI 1.10 to 1.91; I2=0%)
PMID 30878985 · one of two readings recorded this
In-hospital mortality
increases
Subgroup analysis based on study design (p=0.67 for interaction) and ACS subtype (STEMI RR 1.05; 95% CI 0.57 to 1.94; I2=0%; NSTE-ACS RR 1.57; 95% CI 1.15 to 2.14; I2=0% and p=0.25 for interaction) were both non-significant
PMID 30878985 · one of two readings recorded this
In-hospital mortality
no effect, n = 5872
Sensitivity analysis by excluding studies at critical risk of bias showed no differences between morphine and control (RR 1.41; 95% CI 0.87 to 2.27; I2=0%; n=5872 participants)
PMID 30878985 · one of two readings recorded this
In-hospital mortality
no effect
Subgroup analysis based on study design (p=0.67 for interaction) and ACS subtype (STEMI RR 1.05; 95% CI 0.57 to 1.94; I2=0%; NSTE-ACS RR 1.57; 95% CI 1.15 to 2.14; I2=0% and p=0.25 for interaction) were both non-significant
PMID 30878985 · one of two readings recorded this
MACE (cardiovascular mortality, non-fatal MI or non-fatal stroke, PLATO definition) in ACS
increases, RR 1.21, 95% CI 1.02 to 1.45
Not recorded as a finding: cardiovascular composite node is incidence of cardiovascular disease in populations; in-hospital post-ACS MACE treated as a near miss
Adjusted pooled results showed an increased risk of MACE in the morphine group (RR 1.21, 95% CI 1.02 to 1.45; I2=0%).
PMID 30878985 · one of two readings recorded this
major adverse cardiovascular events (cardiovascular death, non-fatal MI or non-fatal stroke, PLATO definition), pooled in ACS
increases, RR 1.21, 95% CI 1.02 to 1.45
Not recorded as a finding: no node for in-hospital MACE composite after ACS; cardiovascular-disease-incidence-composite is for incident disease in general populations
Adjusted pooled results showed an increased risk of MACE in the morphine group (RR 1.21, 95% CI 1.02 to 1.45; I2=0%).
PMID 30878985 · one of two readings recorded this
Major adverse cardiovascular events (MACE)
increases
Adjusted pooled results showed an increased risk of MACE in the morphine group (RR 1.21, 95% CI 1.02 to 1.45; I2=0%)
PMID 30878985 · one of two readings recorded this
Major adverse cardiovascular events (MACE)
increases
Subgroup analysis based on study design (p=0.44 for interaction) and ACS subtype (STEMI RR 1.20; 95% CI 0.71 to 2.03; I2=0%; NSTE-ACS RR 1.21; 95% CI 1.01 to 1.46; I2=0% and p=0.98 for interaction) were both non-significant
PMID 30878985 · one of two readings recorded this
Major adverse cardiovascular events (MACE)
no effect, n = 1952
Sensitivity analysis by excluding studies at critical risk of bias showed no differences between morphine and control (RR 1.40, 95% CI 0.85 to 2.30; I2=0%; n=1952)
PMID 30878985 · one of two readings recorded this
Major adverse cardiovascular events (MACE)
no effect
Subgroup analysis based on study design (p=0.44 for interaction) and ACS subtype (STEMI RR 1.20; 95% CI 0.71 to 2.03; I2=0%; NSTE-ACS RR 1.21; 95% CI 1.01 to 1.46; I2=0% and p=0.98 for interaction) were both non-significant
PMID 30878985 · one of two readings recorded this
major and minor bleeding in ACS
no effect, RR 0.62, 95% CI 0.18 to 2.12 for major bleeding
Not recorded as a finding: no outcome node for bleeding events
No differences were found between morphine and control in the risk of either major (RR 0.62, 95% CI 0.18 to 2.12; I2=0%) or minor (RR 0.62, 95% CI 0.18 to 2.12; I2=40%) bleeding (online supplementary material).
PMID 30878985 · one of two readings recorded this
Major bleeding
no effect
No differences were found between morphine and control in the risk of either major (RR 0.62, 95% CI 0.18 to 2.12; I2=0%)
PMID 30878985 · one of two readings recorded this
Minor bleeding
no effect
or minor (RR 0.62, 95% CI 0.18 to 2.12; I2=40%) bleeding
PMID 30878985 · one of two readings recorded this
Nausea/emesis
no effect
nausea/emesis (RR 1.84; 95% CI 0.80 to 4.23; I2=44%)
PMID 30878985 · one of two readings recorded this
platelet reactivity at 1 and 2 hours, VerifyNow PRU
increases
Not recorded as a finding: no outcome node for platelet reactivity units by VerifyNow
One hour after administration, morphine was associated with increased platelet reactivity, with an MD of 59.37 platelet reactivity units (PRU) (95% CI 36.04 to 82.71; I2=23%).
PMID 30878985 · one of two readings recorded this
platelet reactivity at 1 hour after morphine, VerifyNow platelet reactivity units
increases, MD 59.37 PRU, 95% CI 36.04 to 82.71
Not recorded as a finding: no node for platelet reactivity (PRU by VerifyNow)
One hour after administration, morphine was associated with increased platelet reactivity, with an MD of 59.37 platelet reactivity units (PRU) (95% CI 36.04 to 82.71; I2=23%).
PMID 30878985 · one of two readings recorded this
Platelet reactivity (MEA)
increases
at both 1 hour (MD 27.80, 95% CI 16.03 to 39.57, I2=24%)
PMID 30878985 · one of two readings recorded this
Platelet reactivity (MEA)
increases
2 hours after morphine administration (MD 19.99, 95% CI 1.52 to 38.46, I2=82%)
PMID 30878985 · one of two readings recorded this
Platelet reactivity (VerifyNow)
increases
One hour after administration, morphine was associated with increased platelet reactivity, with an MD of 59.37 platelet reactivity units (PRU) (95% CI 36.04 to 82.71; I2=23%)
PMID 30878985 · one of two readings recorded this
Platelet reactivity (VerifyNow)
increases
Two hours after administration, morphine remained associated with increased platelet reactivity (MD 68.28 PRU, 95% CI 37.01 to 99.55; I2=28%)
PMID 30878985 · one of two readings recorded this
Respiratory insufficiency
no effect
respiratory insufficiency (RR 0.77; 95% CI 0.31 to 1.91; I2=0%)
PMID 30878985 · one of two readings recorded this
Stent thrombosis
no effect
stent thrombosis (RR 1.13; 95% CI 0.67 to 1.92; I2=0%)
PMID 30878985 · one of two readings recorded this
additional benzodiazepine consumption
no effect
additional consumption of benzodiazepines remained almost unchanged throughout the study period at approximately 40%
PMID 30944135 · one of two readings recorded this
adverse mental symptoms
decreases, p = 0.01
(SROM: 0.61±0.56 vs methadone: 0.68±0.60, p<0.01)
PMID 30944135 · one of two readings recorded this
cocaine consumption
decreases, p = 0.001
cocaine (unpublished data: methadone 3.3%, buprenorphine 6%, SROM 3.3%, p<0.001)
PMID 30944135 · one of two readings recorded this
cocaine consumption
decreases, p = 0.0083
consumption of cocaine was significantly reduced to 23.3% (p=0.0083) by day 21
PMID 30944135 · one of two readings recorded this
cocaine craving (brief craving questionnaire)
no effect, p = 0.54
(Visual Analogue Scale: 1.6±2.0 vs 1.4±1.9; brief craving questionnaire 2.1±1.2 vs 2.1±1.2 for methadone and SROM respectively, p=0.54)
PMID 30944135 · one of two readings recorded this
cocaine craving (Visual Analogue Scale)
no effect, p = 0.54
(Visual Analogue Scale: 1.6±2.0 vs 1.4±1.9; brief craving questionnaire 2.1±1.2 vs 2.1±1.2 for methadone and SROM respectively, p=0.54)
PMID 30944135 · one of two readings recorded this
depression score
decreases, p = 0.001
falling from a mean score of 17.84 at baseline to 10.51 at day 21 among patients treated with SROM, p<0.001
PMID 30944135 · one of two readings recorded this
heroin craving (brief craving questionnaire), extension phase end vs start
decreases, p = 0.01
(Visual Analogue Scale: 2.06±2.33 vs 2.70±2.63; brief craving questionnaire 2.25±1.30 vs 2.50±1.43 at the end and start of extension phase respectively, p<0.01)
PMID 30944135 · one of two readings recorded this
heroin craving (brief craving questionnaire)
decreases, p = 0.0001
(Visual Analogue Scale: 3.3±2.4 vs 2.5±2.2; brief craving questionnaire 2.9±1.4 vs 2.6±1.2 for methadone and SROM respectively, p<0.0001)
PMID 30944135 · one of two readings recorded this
heroin craving (Visual Analogue Scale), extension phase end vs start
decreases, p = 0.01
(Visual Analogue Scale: 2.06±2.33 vs 2.70±2.63; brief craving questionnaire 2.25±1.30 vs 2.50±1.43 at the end and start of extension phase respectively, p<0.01)
PMID 30944135 · one of two readings recorded this